Research & Development

Lundbeck’s research and development (R&D) efforts are dedicated to creating new and innovative pharmaceuticals for the treatment of psychiatric and neurological disorders. Through investment and perseverance, we strive to create the very best treatments for patients.

Research is our foundation

Lundbeck is the only fully-integrated pharmaceutical company in the world, solely devoted to the treatment of psychiatric and neurological disorders. We dedicate our entire R&D efforts to develop innovative drugs for the treatment of a number of psychiatric and neurological disorders. Our R&D projects focus on:

  • Alzheimer’s disease
  • Depression 
  • Parkinson’s disease
  • Schizophrenia

Read more about our disease areas.

Underlying disease biology
Lundbeck’s R&D strategy is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of psychiatric and neurological disorders. This approach allows us to treat the symptoms more effectively and also to potentially alter the course of the diseases. The strategy requires comprehensive research into the brain and the biology and mechanisms of psychiatric and neurological disorders, as well as improved understanding of research targets and clinical outcomes.

Strategic alliances
Essential to the R&D strategy is for Lundbeck to maintain strong internal R&D capabilities in order to establish optimal networks and opportunities. We will continue to build external alliances to supplement our internal capabilities, taking advantage of the increased opportunities provided by innovative technologies. Our structure allows us to run extensive co-development pipeline projects, particularly in our alliances with Takeda Pharmaceutical Co., Limited and Otsuka Pharmaceutical Co., Ltd. The structure enables Lundbeck to have more development projects running in tandem, while being able to invest considerably more than what is directly available from our R&D resources.

Future platform
Our R&D strategy will provide a future platform from which Lundbeck can discover and develop drugs with clearly documented effects on biologically defined patient groups. It is expected that society’s demand for this new type of drug will increase. 

See the link on the right-hand side of this page for more information about our pipeline.

Our R&D organization
As a medium-sized pharmaceutical company, we share common values in the way we work worldwide and keep a clear focus on our R&D strategy. Research at Lundbeck is based on the efforts of our multi-disciplinary, empowered project teams, our in-house expertise in the psychiatric and neurological disorders and our state-of-the-art technologies. We work in new, well-equipped laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.

Global presence
Our R&D organization is international and consists of more than 800 dedicated R&D staff. The research organization is located in Copenhagen, Denmark. Development headquarters are also situated in Copenhagen, Denmark with clinical research and regulatory personnel spread worldwide.

Respect for the individual
At Lundbeck R&D, we work together as individuals towards common goals. We seek to constantly develop and improve our scientific and personal skills and qualifications. This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organization. Publication of our scientific results is a natural part of our participation as active members in the international scientific community.

Go to the list of our publications.

Development of a new pharmaceutical product

No. of molecules / No. of patients

Read more about the development process.


By clicking below you will be transferred from the Lundbeck website to the
H. Lundbeck A/S website. Some of the products and compounds displayed on the pipeline page have not been approved by the FDA as being safe or effective for the use under study. The information provided  is for general information only and is not intended to provide medical advice or guidance and should not be used for that purpose. In the United States, a drug is not considered safe or effective for its intended use unless approved by the FDA.


Click here

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.